To say 2017 was a tough year for Celgene Corporation (NASDAQ:CELG) and CELG stock would be a considerable understatement. Despite starting the year on the right foot and advancing 22% as of late September, bad R&D news …
Celgene turned in a brutal third-quarter earnings report, missing revenue forecasts and cutting its long-term profit outlook. Traders were woefully unhedged by several measures, leaving them vulnerable to feel the brunt of the stock's 20% drop. …
Even some of the biggest and best have things go wrong every now and then. Celgene (NASDAQ: CELG) has been the best-performing biotech stock over the last five years among big biotechs with market caps over $50 billion. And now, …
Celgene (NASDAQ: CELG) stock has been in my investment portfolio since 2013. I enjoyed a couple of great years with the biotech stock performing really well. Over the past couple of years, however, Celgene hasn't generated high …
Over the past five years, Celgene (NASDAQ: CELG) stock has soared 280%. That's better than any other biotech with a market cap of $50 billion or more. Celgene's past success stemmed primarily from four drugs: Revlimid, Pomalyst, …
Even though Celgene Corporation (NASDAQ:CELG) presents itself as changing the course of human health through bold pursuits in science, CELG stock is not acting that way. The shares have lost almost 16% since the company reported …
Celgene (NASDAQ: CELG) has long garnered one of the richest valuations among large-cap biotechs, and for good reason. The long and short of it is that Celgene has been able to post industry-leading levels of revenue growth year …
Celgene, a major biotech company, said on Thursday that it planned to stop developing a critical drug. The drug, …